Inhibition of platelet function by A02131-1, a novel inhibitor of cGMP-specific phosphodiesterase, in vitro and in vivo

Blood

Volumn 87, Issue 9, 1996, Pages 3758-3767

  Yu, Sheu Meei ^a   Tsai, Shen Yi ^b   Kuo, Sheng Chu ^b   Ou, Jonathan T ^b  

^a CHANG GUNG UNIVERSITY   (Taiwan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

1 BENZYL 3 (5 HYDROXYMETHYL 2 FURYL)THIENO[3,2 C]PYRAZOLE; 15 HYDROXY 11ALPHA,9ALPHA EPOXYMETHANOPROSTA 5,13 DIENOIC ACID; A 02131 1; ADENOSINE DIPHOSPHATE; ADENOSINE TRIPHOSPHATE; ADENYLATE CYCLASE; ARACHIDONIC ACID; CALCIMYCIN; CYCLIC AMP; CYCLIC GMP; CYCLIC GMP PHOSPHODIESTERASE; GUANYLATE CYCLASE; PHOSPHODIESTERASE I; PHOSPHODIESTERASE INHIBITOR; PROSTAGLANDIN E1; THROMBOCYTE ACTIVATING FACTOR; UNCLASSIFIED DRUG;

ARTICLE; CALCIUM CELL LEVEL; DRUG EFFECT; DRUG SCREENING; ENZYME ACTIVITY; HUMAN; HUMAN CELL; PRIORITY JOURNAL; THROMBOCYTE AGGREGATION; THROMBOCYTE FUNCTION; THROMBOCYTE RICH PLASMA;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; BLOOD PLATELETS; CELLS, CULTURED; HUMANS; MICE; PHOSPHODIESTERASE INHIBITORS; PLATELET ACTIVATION;

EID: 0029876220     PISSN: 00064971     EISSN: None     Source Type: Journal    
DOI: 10.1182/blood.v87.9.3758.bloodjournal8793758     Document Type: Article

References (46)

1. Ross R: The pathogenesis of atherosclerosis - An update. N Engl J Med 314:488, 1986
2. Hirsh J: Hyperreactive platelets and complications of coronary artery disease. N Engl J Med 316:1543, 1987
3. Dinerman JL, Mehta JL: Endothelial, platelet and leukocyte interactions in ischemic heart disease: Insights into potential mechanisms and their clinical relevance. J Am Coll Cardiol 16:207, 1990
4. Baumgartner HR: The role of blood flow in platelet adhesion, fibrin deposition, and formation of mural thrombi. Microvasc Res 5:167, 1973
5. Harrison MJG: Role of platelets and antiplatelet agents in cerebrovascular disease: Clues from trials. Circulation 81:120, 1990 (suppl 1)
6. Cairns JA, Hirsh J, Lewis HD Jr, Resnekov L, Theroux P: Antithrombotic agents in coronary artery disease. Chest 102:456S, 1992
7. Steer ML, Salzman EW: Cyclic nucleotides in hemostasis and thrombosis. Adv Cyclic Nucleotide Res 12:71, 1980
8. Chiang TM, Beachey EH, Kang AH: Interaction of a chick skin collagen fragment (α1-CB5) with human platelets. J Biol Chem 250:6916, 1975
9. Haslam RJ, Davidson MML, McClenaghan MD: Cytochalasin B, the blood platelet release reaction and cyclic GMP. Nature 253:455, 1975
10. Haslam RJ, Davidson MML, Davies T, Lynham JA, McClenaghan MD: Regulation of blood platelet function by cyclic nucleotides. Adv Cyclic Nucleotide Res 9:533, 1978
11. Moncada S, Vane JR: Prostacyclin: Its biosynthesis, actions and clinical potential. Philos T Roy Soc B 294:305, 1981
12. Palmer RMJ, Ferrige AG, Moncada S: Nitric oxide release accounts for the biological activity of endothelium-derived relaxing factor. Nature 327:524, 1987
13. Halbrugge M, Friedrich C, Eigenthaler M, Schanzen-bacher P, Walter U: Stoichiometric and reversible phosphorylation of a 46 kDa protein in human platelets in response to cGMP- and cAMP-elevating vasodilators. J Biol Chem 265:3088, 1990
14. Nolte C, Eigenthaler M, Horstrup K, Honig-Liedl P, Walter U: Synergistic phosphorylation of the focal adhesion-associated vasodilator-stimulated phosphoprotein in intact human platelets in response to cGMP- and cAMP-elevating platelet inhibitors. Biochem Pharmacol 48:1569, 1994
15. Morgan RO, Newby AC: Nitroprusside differentially inhibits ADP-stimulated calcium influx and mobilization in human platelets. Biochem J 258:447, 1989
16. Edgecombe M, Scrutton MC, Kerry R: Platelet-platelet contact is required to observe guanylate cyclase activation in stimulated platelets. Platelets 4:141, 1993
17. Geiger J, Nolte C, Butt E, Sage SO, Walter U: Role of cGMP and cAMP-dependent protein kinase in nitrovasodilator inhibition of agonist-evoked calcium elevation in human platelets. Proc Natl Acad Sci USA 89:1031, 1992
18. Beavo JA, Reifsnyder DH: Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitors. Trends Pharmacol Sci 11:150, 1990
19. Nicholson CD, Challiss RAJ, Shahid M: Differential modulation of tissue function and therapeutic potential of selective inhibitors of cyclic nucleotide phosphodiesterase isoenzymes. Trends Pharmacol Sci 12:19, 1991
20. Macphee CH, Harrison SA, Beavo JA: Immunological identification of the major platelet low-Km cAMP phosphodiesterase: Probable target for antithrombotic agents. Proc Natl Acad Sci USA 83:6660, 1986
21. Hidaka H, Hayashi H, Kohri H, Kimura Y, Hosokawa T, Igawa T, Saitoh Y: Selective inhibitor of platelet cyclic adenosine monophosphate phosphodiesterase, cilostamide, inhibits platelet aggregation. J Pharmacol Exp Ther 211:26, 1979
22. Alvarez R, Banerjee GL, Bruno JJ, Jones GL, Liittschwager JK, Strosberg AM, Venuti MC: A potent and selective inhibitor of cyclic AMP phosphodiesterase with potential cardiotonic and antithrombotic properties. Mol Pharmacol 29:554, 1986
23. Yoshina S, Kuo SC: Studies on heterocyclic compounds. XXXV. Synthesis of furo[3,2-C]pyrazole derivatives. (2) Electrophilic substitution of 1,3-diphenylfuro[3,2-C]pyrazole, Yakugaku Zasshi 98:204, 1978
24. Teng CM, Ko FN: Comparison of the platelet aggregation induced by three thrombin-like enzymes of snake venoms and thrombin. Thromb Haemost 59:304, 1988
25. O'Brien JR: Platelet aggregation II, some results from a new method of study. J Clin Path 15:452, 1962
26. DeLuca M, McElory WD: Purification and properties of firefly luciferase. Methods Enzymol 57:3, 1978
27. 2+ stores using frua-2. Biochem Biophys Res Commun 139:308, 1986
28. 2+ indicators with greatly improved fluorescence properties. J Biol Chem 260:3440, 1985
29. Karniguian A, Legrand YJ, Caen JP: Prostaglandins: Specific inhibition of platelet adhesion to collagen and relationship with cAMP level. Prostaglandins 23:437, 1982
30. Hidaka H, Asano T: Human blood platelet 3′:5′-cyclic nucleotide phosphodiesterase: isolation of low-Km and high-Km phosphodiesterase. Biochem Biophys Acta 429:485, 1976
31. Wells JN, Baird CE, Wu YJ, Hardman JG: Cyclic nucleotide phosphodiesterase activities of pig coronary arteries. Biochem Biophys Acta 384:430, 1975
32. Gerzer R, Hamet P, Ross AH, Lawson JA, Hardman JG: Calcium-induced release from platelet membranes of fatty acid that modulate soluble guanylate cyclase. J Pharmacol Exp Ther 226:180, 1983
33. White AA, Zenser TV: Separation of cyclic 3′,5′-nucleoside monophosphates from other nucleotides on aluminum oxide columns: Application to the assay of adenyl cyclase and guanyl cyclase. Anal Biochem 41:372, 1971
34. Insel PA, Stengel D, Ferry N, Hanoune J: Regulation of adenylate cyclase of human platelet membranes by forskolin. J Biol Chem 257:7485, 1982
35. 3. Prostaglandin 21:727, 1981
36. 2 production. Biochem Pharmacol 31:1158, 1982
37. Berridge MJ: Inositol trisphosphate, diacylglycerol as second messenger. Biochem J 220:345, 1984
38. Nishizuka Y: Turnover of inositol phospholipids and signal transduction. Science 225:1365, 1984
39. Majerus PW, Wilson DB, Connolly TM, Bross TE, Neufeld EJ: Phosphoinositide turnover provides a link in stimulus-response coupling. Trends Biochem Sci 10:168, 1985
40. Vane JR, Aanggard EE, Botting RM: Regulatory functions of the vascular endothelium. N Engl J Med 323:27, 1990
41. Ignarro LJ: Signal transduction mechanisms involving nitric oxide. Biochem Pharmacol 41:485, 1991
42. Yu SM, Chen CC, Ko FN, Huang YL, Huang TF, Teng CM: Dicentrine, a novel antiplatelet agent inhibiting thromboxane formation and increasing the cAMP level of rabbit platelets. Biochem Pharmacol 43:323, 1992
43. 2 potentiates platelet aggregation by priming protein kinase C. Blood 82:2704, 1993
44. Grabowska RP, Gear ARL: Role of cyclic nucleotides in rapid platelet adhesion to collagen. Blood 83:2508, 1994
45. Maurice DH, Haslam RJ: Molecular basis of the synergistic inhibition of platelet function by nitrovasodilators and activators of adenylate cyclase: Inhibition of cyclic AMP breakdown by cyclic GMP. Mol Pharmacol 37:671, 1990
46. Saitoh S, Saito T, Otake A, Owada T, Mitsugi M, Hashimoto H, Maruyama Y: Cilostazol, a novel cyclic AMP phosphodiesterase inhibitor, prevents reocclusion after coronary arterial thrombolysis with recombinant tissue-type plasminogen activator. Arterioscler Thromb 13:563, 1993